scibase:-year-end-report

Scibase: Year-end report

 

The fourth quarter in figures:

  • Net sales amounted to TSEK 3,055 (2,800).
  • The loss after tax amounted to TSEK 9,839 (10,207).
  • The loss per share amounted to SEK 0.20 (0.61).
  • The cash flow from current operations was negative in the amount of TSEK 10,290 (8,842).
  • The gross margin reached 49.4% (58.0%).
  • Electrode sales volume increased by 4% and reached 7,492 (7,180) units. Repeat sales of electrodes to existing customers increased by 6%.

The full year in figures:

  • Net sales amounted to TSEK 9,521 (9,276).
  • The loss after tax amounted to TSEK 34,989 (39,594).
  • The loss per share amounted to SEK 1.12 (2.38).
  • The cash flow from current operations was negative in the amount of TSEK 33,861 (37,956).
  • The gross margin reached 52.5% (54.5%).
  • Electrode sales volume increased by 8% and reached 25,686 (23,724) units. Repeat sales of electrodes to existing customers increased by 9%.

Important events during the quarter:

  • The negative impact of Covid-19 seen in the first half of the year lessened in Q3 and in Q4 sales reached a new quarterly high. Sales in the company’s key market Germany increased by 15% while overall sales increased by 9%. The market situation however remains difficult to predict going forward, due to ongoing lockdowns and reduced marketing activities.
  • SciBase announced the outcome of the exercise of warrants of series TO1. In total 91.4% of the warrants were subscribed for at a price of SEK 1.75, raising MSEK 30 net.Nevisense Go, SciBase’s next generation handheld platform, was released at the end of October. The first version of Nevisense Go will be used by researchers and industrial partners to assess skin barrier function.
  • SciBase was granted a Category III CPT® code for the Nevisense melanoma detection test in the US.
  • Two US studies showing improved detection of melanoma by clinicians with Nevisense were published in leading US journals. The studies compared the evaluation of atypical, pigmented skin lesions using visual evaluation alone to visual evaluation plus Nevisense.
  • The first study validating the use of Nevisense in Non-melanoma skin cancer was published.
  • Nevisense was included in infant study at Mount Sinai Hospital in New York. Nevisense will be used to measure skin properties including barrier function and evaluate whether these measurements can help predict the development of allergies or monitor their progress.
  • Linn Olsen, SciBase’s head of production and supply chain, has been appointed as a member of the management team.

Important events after the end of the  period

  • A further German study evaluating the value of using Nevisense on suspected Non-melanoma skin cancer (NMSC, also known as Keratinocyte cancer) in normal clinical practice was published.
  • A nominating committee was appointed.

July 1 – Sep 30

Jan 1 – Sep 30

THE GROUP

2020

2019

2020

2019

Net sales, SEK ths

3 055

2 800

9 521

9 276

Gross margin, %

49,4%

58,0%

52,5%

54,5%

Equity/Asset ratio, %

79,1%

69,4%

79,1%

69,4%

Net indebtness, multiple

0,26

0,44

0,26

0,44

Cash equivalents, SEK ths

41 427

26 456

41 427

26 456

Cashflow from operating activities, SEK ths

-10 290

-8 842

-33 861

-37 956

Earnings per share (before and after dilution), SEK

-0,20

-0,61

-1,12

-2,38

Shareholder’s equity per share, SEK

0,96

1,93

1,50

1,93

Average number of shares, 000′

48 707

16 618

31 287

16 618

Number of shares at closing of period, 000′

54 780

16 618

54 780

16 618

Share price at end of period, SEK

4,62

4,36

4,62

4,36

Number of sold electrodes, pieces

7 492

7 180

25 686

23 724

Average number of employees

17

18

16

18

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on February 19, 2021.Contact person: Michael Colérus, CFO. +46 70 341 34 72

Leave a Reply

Your email address will not be published. Required fields are marked *